The eligibility of the other activated kinases as therapeutic targets in ccRCC is not as well understood although preclinical studies demonstrate the potential of candidate kinase identified in the current study including AXL, ALK1, and MET. The gene discussed is AXL; the disease is nonpapillary renal cell carcinoma.